News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Analyst Makes A Trip To Sweden, Returns Home Predicting Vertex Pharmaceuticals (MA) (VRTX) Cystic Fibrosis Drug Failure


6/17/2014 6:36:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Bernstein analyst Geoff Porges hung out with doctors and cystic fibrosis experts at the just-concluded European Cystic Fibrosis Society conference in Sweden and returned home even more bearish on Vertex Pharmaceuticals (VRTX). In a research note Monday, Porges lays out reasons why the super-important combination studies of Kalydeco and VX-809 -- TRAFFIC and TRANPORT -- are more likely to fail.

Hey, check out all the research scientist jobs. Post your resume today!

Read at The Street.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES